{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:24:06Z","timestamp":1719015846847},"reference-count":32,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>To evaluate the efficacy and safety of Brolucizumab for neovascular age-related macular degeneration (n-AMD) through a systematic review and meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods<\/jats:title>\n<jats:p>Cochrane, PubMed, Embase, and Web of Science databases were comprehensively searched for relevant studies. Stata and RevMan5.4 were applied for meta-analysis and risk of bias assessment. Data on the best-corrected visual acuity (BCVA), central subfield thickness (CSFT), presence of intraretinal fluid (IRF) and\/or subretinal fluid (SRF), participants with \u22651 serious adverse events, and participants with \u22651 adverse events were analyzed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Six studies were finally included. Meta-analysis showed statistical differences in BCVA [SMD = \u22120.65, 95% CI [\u22120.17 to \u22120.23], <jats:italic>P<\/jats:italic> &lt; 0.05], the presence of IRF and\/or SRF [RR = 0.67, 95% CI [0.56\u20130.79], <jats:italic>P<\/jats:italic> &lt; 0.05], and the safety of participants with \u22651 serious adverse events [RR = 0.57, 95% CI [0.39\u20130.84], <jats:italic>P<\/jats:italic> &lt; 0.05] between the experimental group and the control group. However, no statistical differences were observed in CSFT [SMD = \u22121.16, 95% CI [\u22122.79 to 0.47], <jats:italic>P<\/jats:italic> &gt; 0.05] or the safety of participants with \u22651 adverse events [RR = 1.07, 95% CI [0.97\u20131.17], <jats:italic>P<\/jats:italic> &gt; 0.05].<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Compared to other anti-VEGF drugs such as Aflibercept and Ranibizumab, intravitreal injection of 6 mg Brolucizumab is more effective and safer for n-AMD, especially in the presence of IRF and\/or SRF, and for participants with \u22651 serious adverse events.<\/jats:p>\n<\/jats:sec>","DOI":"10.7717\/peerj.17561","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:01:47Z","timestamp":1718953307000},"page":"e17561","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Brolucizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis"],"prefix":"10.7717","volume":"12","author":[{"given":"Ran","family":"Dou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"10","key":"10.7717\/peerj.17561\/ref-1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1080\/02713683.2020.1731832","article-title":"Comparison of the efficacy of brolucizumab with natural disease progression in wet AMD using clinical data from the phase III HAWK and HARRIER trials and modelled placebo data","volume":"45","author":"Agostini","year":"2020","journal-title":"Current Eye Research"},{"issue":"3","key":"10.7717\/peerj.17561\/ref-2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/IAE.0000000000003344","article-title":"Changes in systemic levels of vascular endothelial growth factor after intravitreal injection of aflibercept or brolucizumab for neovascular age-related macular degeneration","volume":"42","author":"Angermann","year":"2022","journal-title":"Retina"},{"issue":"10","key":"10.7717\/peerj.17561\/ref-3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"issue":"8","key":"10.7717\/peerj.17561\/ref-4","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00417-022-05634-5","article-title":"Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab","volume":"260","author":"Boltz","year":"2022","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"14","key":"10.7717\/peerj.17561\/ref-5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.7717\/peerj.17561\/ref-6","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/bjophthalmol-2020-318672","article-title":"Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study","volume":"106","author":"Bulirsch","year":"2022","journal-title":"British Journal of Ophthalmology"},{"key":"10.7717\/peerj.17561\/ref-7","article-title":"Esba1008 microvolume study","author":"ClinicalTrials.gov","year":"2013"},{"key":"10.7717\/peerj.17561\/ref-8","article-title":"Study of safety and efficacy of brolucizumab 6 mg drug product intended for commercialization in patients with namd","author":"ClinicalTrials.gov","year":"2019"},{"issue":"9","key":"10.7717\/peerj.17561\/ref-9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"3","key":"10.7717\/peerj.17561\/ref-10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/IAE.0000000000003349","article-title":"Effect of retinal thickness variability on visual outcomes and fluid persistence in neovascular age-related macular degeneration","volume":"42","author":"Dugel","year":"2022","journal-title":"Retina"},{"issue":"1","key":"10.7717\/peerj.17561\/ref-11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"12","key":"10.7717\/peerj.17561\/ref-12","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/jcm10122666","article-title":"Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6 month outcomes","volume":"10","author":"Haensli","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"12","key":"10.7717\/peerj.17561\/ref-13","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.7717\/peerj.17561\/ref-14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"10.7717\/peerj.17561\/ref-15","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00417-022-05591-z","article-title":"A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study","volume":"260","author":"Holz","year":"2022","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.7717\/peerj.17561\/ref-16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the iris registry and komodo healthcare map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmology"},{"issue":"6","key":"10.7717\/peerj.17561\/ref-17","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00417-021-05518-0","article-title":"Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD","volume":"260","author":"Khoramnia","year":"2022","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"5","key":"10.7717\/peerj.17561\/ref-18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/jcph.2002","article-title":"Effect of anti-VEGF therapy on the disease progression of neovascular age-related macular degeneration: a systematic review and model-based meta-analysis","volume":"62","author":"Luu","year":"2022","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.7717\/peerj.17561\/ref-19","doi-asserted-by":"publisher","first-page":"720345","DOI":"10.3389\/fphar.2021.720345","article-title":"Short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice","volume":"12","author":"Montesel","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"10.7717\/peerj.17561\/ref-20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK","volume":"106","author":"Ogura","year":"2022","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.7717\/peerj.17561\/ref-21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10384-022-00908-1","article-title":"Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration","volume":"66","author":"Ota","year":"2022","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"6","key":"10.7717\/peerj.17561\/ref-22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40259-021-00499-2","article-title":"Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update","volume":"35","author":"Parravano","year":"2021","journal-title":"BioDrugs"},{"issue":"21","key":"10.7717\/peerj.17561\/ref-23","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms21218242","article-title":"Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches","volume":"21","author":"Ricci","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"14","key":"10.7717\/peerj.17561\/ref-24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.7717\/peerj.17561\/ref-25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1517\/14656566.2015.1067679","article-title":"Advances in pharmacotherapy for wet age-related macular degeneration","volume":"16","author":"Santarelli","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.7717\/peerj.17561\/ref-26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","article-title":"Brolucizumab-early real-world experience: BREW study","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.7717\/peerj.17561\/ref-27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/OPTH.S345403","article-title":"Effectiveness of current treatments for wet age-related macular degeneration in japan: a systematic review and pooled data analysis","volume":"16","author":"Takahashi","year":"2022","journal-title":"Clinical Ophthalmology"},{"issue":"6","key":"10.7717\/peerj.17561\/ref-28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","article-title":"Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study","volume":"260","author":"Tamashiro","year":"2022","journal-title":"Graefes Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.7717\/peerj.17561\/ref-29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"issue":"6","key":"10.7717\/peerj.17561\/ref-30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.18553\/jmcp.2021.27.6.743","article-title":"Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis","volume":"27","author":"Yu","year":"2021","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"2","key":"10.7717\/peerj.17561\/ref-31","doi-asserted-by":"publisher","first-page":"e00897","DOI":"10.1002\/prp2.897","article-title":"Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration","volume":"10","author":"Zakaria","year":"2022","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.7717\/peerj.17561\/ref-32","doi-asserted-by":"publisher","first-page":"797108","DOI":"10.3389\/fphar.2021.797108","article-title":"Efficacy and safety of anti-vascular endothelial growth factor monotherapies for neovascular age-related macular degeneration: a mixed treatment comparison","volume":"12","author":"Zhang","year":"2021","journal-title":"Frontiers in Pharmacology"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/17561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17561.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17561.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:01:53Z","timestamp":1718953313000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/17561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":32,"alternative-id":["10.7717\/peerj.17561"],"URL":"https:\/\/doi.org\/10.7717\/peerj.17561","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"article-number":"e17561"}}